Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-03-31 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $5.5B | $5.1B | $4.7B | $4.2B | $3.6B | $3.2B | $3.0B | $2.6B | $2.3B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B | $1.4B | $1.2B | $1.1B | $921M | $835M | $716M | $607M |
| Bruttoergebnis | $3.4B | $3.1B | $2.7B | $2.4B | $2.0B | $1.8B | $1.7B | $1.5B | $1.4B | $1.2B | $1.1B | $1.0B | $990M | $941M | $821M | $741M | $655M | $554M | $494M | $384M | $377M |
| Bruttomarge % | 61.7% | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% | 58.1% | 59.0% | 58.2% | 58.1% | 58.0% | 60.2% | 63.6% | 62.1% | 60.0% | 59.6% | 60.0% | 60.2% | 59.1% | 53.7% | 62.1% |
| Betriebsergebnis (EBIT) | $1.9B | $1.7B | $1.3B | $1.1B | $1.0B | $904M | $810M | $579M | $542M | $426M | $429M | $409M | $405M | $355M | $294M | $267M | $240M | $190M | $143M | $90M | $131M |
| Operative Marge % | 34.3% | 32.8% | 28.2% | 26.8% | 28.0% | 28.3% | 27.4% | 22.2% | 23.2% | 20.6% | 23.3% | 24.4% | 26.1% | 23.4% | 21.5% | 21.5% | 22.0% | 20.7% | 17.1% | 12.6% | 21.6% |
| Jahresüberschuss | $1.5B | $1.4B | $1.0B | $898M | $779M | $475M | $622M | $405M | $316M | $342M | $352M | $353M | $345M | $307M | $255M | $227M | $190M | $146M | $110M | $66M | $88M |
| Nettomarge % | 27.4% | 27.2% | 21.8% | 21.2% | 21.8% | 14.8% | 21.0% | 15.5% | 13.5% | 16.6% | 19.2% | 21.0% | 22.2% | 20.3% | 18.6% | 18.3% | 17.4% | 15.9% | 13.2% | 9.3% | 14.5% |
| EBITDA | $2.2B | $1.9B | $1.5B | $1.4B | $1.2B | $1.1B | $990M | $706M | $680M | $569M | $541M | $482M | $485M | $470M | $423M | $374M | $322M | $190M | $205M | $90M | $174M |
| Ergebnis je Aktie (EPS) | $10.33 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 | $2.49 | $2.47 | $2.39 | $2.10 | $1.71 | $1.44 | $1.23 | $0.95 | $0.70 | $0.42 | $0.57 |
| Ausstehende Aktien (Mio.) | 147M | 147M | 148M | 147M | 147M | 146M | 146M | 144M | 144M | 142M | 142M | 143M | 144M | 146M | 149M | 157M | 155M | 154M | 157M | 157M | 154M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für RMD. /companies/us/RMD
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms